Kingdom. E-mail addresses; l.j.leslie@aston.ac.uk; vasanthp@aston.ac.uk; jacksop1@aston.ac.uk; mabialaa@aston.ac.uk; pallettr@aston.ac.uk; stillmac@aston.ac.uk; l.marshall@aston.ac.uk
A comparative study of electronic cigarette vapour extracts on airwayrelated cell lines in vitroThe use of electronic cigarettes (ECs) is rapidly increasing worldwide, however scientific evidence regarding EC cytotoxicity is limited. The aim of this study was to evaluate the acute cytotoxicity of EC vapour extract (ECE) on airway-related cells in vitro.Cigarette smoke extract (CSE), vapour extract of fifteen brands/flavours of ECs and the extract from the E-vehicle (propylene glycol and glycerine) was collected. Extracts, in concentrations of 100% to 12.5%, were added to human bronchial epithelial (BEAS-2B, IB3-1 and C38), fibroblast (Wi-38) and macrophage (J774 and THP-1) cell lines.Viability was assessed after 24 hours using a standard XTT assay. Viability of less than 70% of control (no extract) was considered cytotoxic according to UNI EN ISO 10993-5 standards.CSE displayed a concentration-dependent influence on cell viability across all four cell lines with 100% producing the most toxic effect, therefore validating the model. ECEs reduced viability although this was not correlated with nicotine content or the Evehicle. However, several flavours proved cytotoxic, with variation between different brands and cell lines.These data indicate that not all ECs are the same and that use of a particular flavour or brand may have differing effects. The cell line used is also an important factor. More research is crucial to ascertain the health effects of different ECs before they can be accepted as a safe alternative to tobacco cigarettes.Keywords: Electronic cigarettes; airways; cytotoxicity; epithelials; in vitro models 3
IntroductionElectronic cigarettes (EC) first emerged onto the market in China in 2004 and entered the US market in 2007 (Regan et al. 2013). Advertised as a safe alternative to traditional tobacco cigarettes, EC were soon introduced across different countries and their market has steadily risen. According to the UK's public health charity, Action on Smoking and Health (ASH), 2.6 million adults in Great Britain currently use EC (ASH 2015). There has been a rapid global progression amongst high and low income countries, with EC use stabilising at around 17% of adult smokers, although awareness of these products is much higher, according to data pulled together in a recent Public Health England report (Britton and Bogdanovica 2014).The body of research performed on the acute and chronic effects of ECs on human health is limited (Breland et al. 2014). There are a number of challenges associated with EC research. The lack of a standardised testing protocol to evaluate different products means that there is no consensus between academic researchers, manufacturers and stake-holders (Orr 2014). Proper toxicological evaluations of ECs by the regulatory bodies are also lacking.The liquid component of EC, known as E-liq...